Denali Therapeutics Inc. Stock-Based Compensation
Denali Therapeutics Inc. (DNLI) reported Stock-Based Compensation of $46.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $22.91M, a 9.74% decline year-over-year.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $23.09M, a 8.24% decline year-over-year.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $23.95M, a 4.49% decline year-over-year.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $25.14M, a 1.11% increase year-over-year.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $99.63M, a 3.15% decline from fiscal 2024.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $102.88M, a 4.83% decline from fiscal 2023.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $108.10M, a 8.27% increase from fiscal 2022.
- Denali Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $99.85M, a 17.13% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $46.00M 10-Q · filed 2026-08-06 | $69.95M derived: sum of 3 quarters · filed 2026-08-06 | $95.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $23.09M 10-Q · filed 2026-05-07 | $47.04M derived: sum of 2 quarters · filed 2026-05-07 | $72.17M derived: sum of 3 quarters · filed 2026-05-07 | $97.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.09M derived: sum of 2 quarters · filed 2026-02-26 | $74.47M derived: sum of 3 quarters · filed 2026-08-06 | $99.63M 10-K · filed 2026-02-26 |
| 2025-09-30 | $25.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $50.52M derived: sum of 2 quarters · filed 2026-08-06 | $75.68M 10-Q · filed 2025-11-06 | $100.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $50.55M 10-Q · filed 2026-08-06 | $75.63M derived: sum of 3 quarters · filed 2026-08-06 | $100.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.16M 10-Q · filed 2026-05-07 | $50.24M derived: sum of 2 quarters · filed 2026-05-07 | $75.10M derived: sum of 3 quarters · filed 2026-05-07 | $100.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $25.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.94M derived: sum of 2 quarters · filed 2026-02-26 | $75.04M derived: sum of 3 quarters · filed 2026-02-26 | $102.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | $24.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.96M derived: sum of 2 quarters · filed 2025-11-06 | $77.80M 10-Q · filed 2025-11-06 | $103.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $25.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $52.94M 10-Q · filed 2025-08-11 | $78.93M derived: sum of 3 quarters · filed 2026-02-26 | $106.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $27.84M 10-Q · filed 2025-05-06 | $53.83M derived: sum of 2 quarters · filed 2026-02-26 | $81.29M derived: sum of 3 quarters · filed 2026-02-26 | $107.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $25.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $53.45M derived: sum of 2 quarters · filed 2026-02-26 | $80.02M derived: sum of 3 quarters · filed 2026-02-26 | $108.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $27.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $54.03M derived: sum of 2 quarters · filed 2024-11-06 | $82.11M 10-Q · filed 2024-11-06 | $107.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $26.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $54.65M 10-Q · filed 2024-08-01 | $79.84M derived: sum of 3 quarters · filed 2025-02-27 | $104.42M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $28.08M 10-Q · filed 2024-05-07 | $53.27M derived: sum of 2 quarters · filed 2025-02-27 | $77.85M derived: sum of 3 quarters · filed 2025-02-27 | $101.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $25.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $49.77M derived: sum of 2 quarters · filed 2025-02-27 | $73.70M derived: sum of 3 quarters · filed 2025-02-27 | $99.85M 10-K · filed 2025-02-27 |
| 2022-09-30 | $24.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $48.52M derived: sum of 2 quarters · filed 2023-11-07 | $74.66M 10-Q · filed 2023-11-07 | $96.75M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $23.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $50.08M 10-Q · filed 2023-08-08 | $72.17M derived: sum of 3 quarters · filed 2024-02-28 | $93.16M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $26.14M 10-Q · filed 2023-05-08 | $48.23M derived: sum of 2 quarters · filed 2024-02-28 | $69.23M derived: sum of 3 quarters · filed 2024-02-28 | $90.36M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $22.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $43.08M derived: sum of 2 quarters · filed 2024-02-28 | $64.22M derived: sum of 3 quarters · filed 2024-02-28 | $85.25M 10-K · filed 2024-02-28 |
| 2021-09-30 | $21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $42.13M derived: sum of 2 quarters · filed 2022-11-03 | $63.16M 10-Q · filed 2022-11-03 | $76.99M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $21.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $42.16M 10-Q · filed 2022-08-08 | $55.99M derived: sum of 3 quarters · filed 2023-02-27 | $69.25M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $21.03M 10-Q · filed 2022-05-05 | $34.86M derived: sum of 2 quarters · filed 2023-02-27 | $48.11M derived: sum of 3 quarters · filed 2023-02-27 | $60.59M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $13.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $27.08M derived: sum of 2 quarters · filed 2023-02-27 | $39.57M derived: sum of 3 quarters · filed 2023-02-27 | $50.35M 10-K · filed 2023-02-27 |
| 2020-09-30 | $13.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $25.74M derived: sum of 2 quarters · filed 2021-11-04 | $36.52M 10-Q · filed 2021-11-04 | $45.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $12.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $23.27M 10-Q · filed 2021-08-04 | $32.16M derived: sum of 3 quarters · filed 2022-02-28 | $41.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $10.79M 10-Q · filed 2021-05-05 | $19.67M derived: sum of 2 quarters · filed 2022-02-28 | $28.57M derived: sum of 3 quarters · filed 2022-02-28 | $42.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $8.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $17.79M derived: sum of 2 quarters · filed 2022-02-28 | $31.50M derived: sum of 3 quarters · filed 2022-02-28 | $38.38M 10-K · filed 2022-02-28 |
| 2019-09-30 | $8.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $22.61M derived: sum of 2 quarters · filed 2020-11-05 | $29.49M 10-Q · filed 2020-11-05 | $35.13M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $13.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $20.59M 10-Q · filed 2020-08-07 | $26.23M derived: sum of 3 quarters · filed 2021-02-26 | $31.74M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $6.87M 10-Q · filed 2020-05-07 | $12.52M derived: sum of 2 quarters · filed 2021-02-26 | $18.03M derived: sum of 3 quarters · filed 2021-02-26 | $22.74M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $11.16M derived: sum of 2 quarters · filed 2021-02-26 | $15.87M derived: sum of 3 quarters · filed 2021-02-26 | $18.79M 10-K · filed 2021-02-26 |
| 2018-09-30 | $5.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $10.22M derived: sum of 2 quarters · filed 2019-11-06 | $13.14M 10-Q · filed 2019-11-06 | $14.60M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $4.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $7.63M 10-Q · filed 2019-08-06 | $9.09M derived: sum of 3 quarters · filed 2020-02-27 | $10.22M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.92M 10-Q · filed 2019-05-08 | $4.38M derived: sum of 2 quarters · filed 2020-02-27 | $5.51M derived: sum of 3 quarters · filed 2020-02-27 | $6.57M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $2.58M derived: sum of 2 quarters · filed 2020-02-27 | $3.64M derived: sum of 3 quarters · filed 2020-02-27 | $4.41M 10-K · filed 2020-02-27 |
| 2017-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.19M derived: sum of 2 quarters · filed 2018-11-08 | $2.95M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.82M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $765.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $2.95M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |